June 28, 2018 / 8:38 PM / 3 months ago

BRIEF-Novartis Presents New Data Demonstrating Long-Term Efficacy Of Aimovig

June 28 (Reuters) - Novartis AG:

* NOVARTIS PRESENTS NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG® (ERENUMAB) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE

* NOVARTIS AG -SAFETY RESULTS AFTER ONE YEAR WERE CONSISTENT WITH ESTABLISHED SAFETY PROFILE OF AIMOVIG IN PREVIOUS STUDIES.

* NOVARTIS - AIMOVIG SHOWED ROBUST EFFICACY IN PATIENTS WITH CHRONIC MIGRAINE, WITH SUBSTANTIAL REDUCTIONS IN MONTHLY MIGRAINE DAYS SUSTAINED THROUGHOUT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below